
News|Articles|February 3, 2025
Data-Driven Insights can Optimize Clinical Trial Site Selection
Author(s)PurpleLab
Clinical trials are crucial for drug development but often face delays due to poor site selection, which can lead to protocol violations, poor data quality, and increased costs. Ninety percent of clinical trials fail to meet their timelines, and issues like inadequate staffing and patient recruitment are significant challenges. Traditional site selection methods are inefficient, and the COVID-19 pandemic has further complicated the process. Data-driven insights can optimize site selection by evaluating current data on patient populations, investigators, and site capabilities.
Trending on Applied Clinical Trials Online
1
Tapping the Global Potential of China’s Biotech Surge
2
2026 DIA Global Annual Meeting: What the FDA's Real-Time Data Push Actually Means for Sponsors and CROs
3
2026 DIA Global Annual Meeting: Why Protocol Digitization Has Been So Hard to Automate—Until Now
4
ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure
5